CTRI/2017/07/008985已完成未知
A Randomized, Open Label, Single-Dose, Two Period, Two Treatment, Two Sequence, Cross-over, Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety of Rabeprazole Sodium Delayed-release Capsule 20 mg of Cadila Healthcare Limited with ACIPHEX® (Rabeprazole Sodium) Delayed-release Tablet 20 mg of Eisai Inc. in Healthy Volunteers.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Age: 18 to 45 years old, both inclusive.
- •2. Sex: Male subjects
- •3. BMI: 18.5 to 30.0 weight in kg/(height in meter)2 both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5)
- •4. Able to communicate effectively with study personnel
- •5. Able to give written informed consent to participate in the study.
- •6. Subjects with negative results for H. pylori IgG antibody at screening
- •7. Subjects judge by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication.
排除标准
- •1. History of allergic responses to rabeprazole or similar drugs or other constituents of the formulation.
- •2. Have significant diseases or clinically significant abnormal finding during screening medical history, physical examination, laboratory evaluations, ECG and chest X-ray recording.
- •3. Any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •4. History or presence of bronchial asthma.
- •5. A depot injection or implant of any drug within 3 months prior to the first dose of study medication.
- •6. Use of enzyme-modifying drugs within 30 days prior to the first dose of study medication.
- •7. History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
- •8. Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period.
- •9. History of difficulty with donating blood or difficulty in accessibility of veins.
- •10. A positive hepatitis screen (includes subtypes B & C).
- •11. A positive test result for HIV antibody and / or syphilis (RPR/VDRL).
- •12. Volunteer who have received a known Investigational drug within ten elimination half life of the administered drug prior to the first dose of study medication or have donated blood or loss of blood 50 mL to 100 mL within 30 days or 101 mL to 200 mL within 60 days or >200 mL within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
- •13. History of difficulty in swallowing or of any gastrointestinal disease which could affect drug absorption.
- •14. Intolerance to venipuncture.
- •15. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Sub-Investigator, could contraindicate the volunteerâ??s participation in this study.
- •16. Any other condition that, in the investigatorâ??s judgment, might increase the risk to the subject or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
研究者
相似试验
已完成
不适用
Pharmacokinetic study of SPARC1613 and Reference1613CTRI/2016/12/007565Sun Pharma Advanced Research Company Limited142
Unknown
1 期
A Randomized, Open Label,Two Period, Single Dose Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane® in Patients with Breast CancerCTRI/2014/04/004528Sun Pharma Advanced Research Company Ltd72
Unknown
1 期
Bioavailability Study of Paclitaxel Injection Concentrate for Suspension in Subjects with Locally Recurrent or Metastatic Breast Cancer.CTRI/2020/03/024065Sun Pharma Advanced Research Company Limited
已完成
不适用
Clinical research study of SPARC1612 in breast cancerCTRI/2016/06/007043Sun Pharma Advanced Research Company Ltd28
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-period, Two-sequence Crossover Bioequivalence Study of Generic Linagliptin/Metformin Hydrochloride Tablets 2.5 mg/1000 mg and Reference Product (TRAJENTA DUO) in Healthy Thai Volunteers under Fed ConditionsBioequivalence Study Healthy Thai VolunteersTCTR20231012008International Bio Service Co., Ltd.40